Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, sham-controlled, double-blind study of NRTX-1001 in people living with drug-resistant mesial temporal lobe epilepsy (MTLE)

Next Previous
Trial Profile

A phase 3 randomized, sham-controlled, double-blind study of NRTX-1001 in people living with drug-resistant mesial temporal lobe epilepsy (MTLE)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRTX-1001 (Primary)
  • Indications Temporal-lobe-epilepsy
  • Focus Therapeutic Use
  • Acronyms EPIC

Most Recent Events

  • 03 Apr 2025 According to a Neurona Therapeutics media release, the company is preparing to recruit patients in 2H 2025.
  • 03 Apr 2025 According to a Neurona Therapeutics media release, the company has received $102 million financing to fuel this trial and advance regenerative cell therapy pipeline. This round recognizes recent FDA alignment to advance NRTX-1001 into this trial.
  • 26 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top